"Severity" in adult sickle cell disease.

Martin H. Steinberg is a consultant for Fulcrum Therapeutics, Cellarity, and Vertex Pharmaceuticals. He is a member of the Steering Committee for the gene therapy trial of CTX001 (exa-cel) sponsored by Vertex. Mark T. Gladwin is a co-inventor of patents and patent applications directed to the use of recombinant neuroglobin and heme-based molecules as antidotes for CO poisoning, which have been licensed by Globin Solutions, Inc. Dr. Gladwin is a shareholder, advisor, and director in Globin Solutions, Inc. Dr. Gladwin is also co-inventor on patents directed to the use of nitrite salts in cardiovascular diseases, which were previously licensed to United Therapeutics, and is now licensed to Globin Solutions and Hope Pharmaceuticals. Dr. Gladwin is a principal investigator in a research collaboration with Bayer Pharmaceuticals to evaluate riociguate as a treatment for patients with SCD. None.